Form 8-K - Current report:
SEC Accession No. 0001213900-22-006177
Filing Date
2022-02-09
Accepted
2022-02-09 16:59:35
Documents
21
Period of Report
2022-02-09
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea155225-8k_longeveron.htm   iXBRL 8-K 26395
2 NEWSLETTER- FEBRUARY 2022 ea155225ex99-1_longeveron.htm EX-99.1 7356
6 GRAPHIC ex99-1_001.jpg GRAPHIC 216993
7 GRAPHIC ex99-1_002.jpg GRAPHIC 394550
8 GRAPHIC ex99-1_003.jpg GRAPHIC 512677
9 GRAPHIC ex99-1_004.jpg GRAPHIC 390448
10 GRAPHIC ex99-1_005.jpg GRAPHIC 435498
11 GRAPHIC ex99-1_006.jpg GRAPHIC 360868
12 GRAPHIC ex99-1_007.jpg GRAPHIC 236418
13 GRAPHIC ex99-1_008.jpg GRAPHIC 396869
  Complete submission text file 0001213900-22-006177.txt   4233015

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE lgvn-20220209.xsd EX-101.SCH 3039
4 XBRL LABEL FILE lgvn-20220209_lab.xml EX-101.LAB 34476
5 XBRL PRESENTATION FILE lgvn-20220209_pre.xml EX-101.PRE 22599
15 EXTRACTED XBRL INSTANCE DOCUMENT ea155225-8k_longeveron_htm.xml XML 3712
Mailing Address 1951 NW 7TH AVENUE SUITE 520 MIAMI FL 33136
Business Address 1951 NW 7TH AVENUE SUITE 520 MIAMI FL 33136 305-302-7158
Longeveron Inc. (Filer) CIK: 0001721484 (see all company filings)

EIN.: 472174146 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40060 | Film No.: 22607992
SIC: 2834 Pharmaceutical Preparations